Boston Therapeutics, Inc. (BTHE) Stock

About Boston Therapeutics, Inc.

Founded in 2009 and headquartered in Lawrence, Massachusetts, Boston Therapeutics, Inc. operates as a pre-clinical and clinical-stage pharmaceutical development firm. The company specializes in the development, manufacturing, and commercialization of carbohydrate-based therapeutic drugs and dietary supplements within the United States. Its pipeline features several key drug candidates: BTI-320, a non-systemic carbohydrate compound currently in Phase IIb clinical trials, engineered to mitigate post-meal increases in blood glucose levels for patients with Type 2 diabetes and pre-diabetes; BTI-410, an injectable peptide compound that has completed Phase Ib clinical trials, developed for Type 1 immunosuppression therapy post-kidney transplant and for Type 2 diabetes patients; and IPOXYN, an injectable carbohydrate drug designed to prevent necrosis (cell death) and alleviate hypoxic conditions such as diabetic foot ulcers and other vascular/neurological complications. Furthermore, Boston Therapeutics markets SUGARDOWN, a non-systemic complex carbohydrate dietary supplement supporting healthy post-meal blood glucose levels. The company previously operated as Avanyx Therapeutics, Inc. before adopting its current name in November 2010.

the stock is valued at a price-to-earnings (P/E) ratio of -1.00, price-to-book of -0.13, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.01 and $0.01, and currently trades at its 52-week high.

On profitability, Boston Therapeutics, Inc. generates a return on equity (ROE) of 11.11%, return on capital employed of 9.16%.

Official website: www.bostonti.com